# Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

> **NCT05560607** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 19 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease
- Fatty Liver, Nonalcoholic
- NAFLD
- Nonalcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
- NASH

## Interventions

- **DRUG:** AZD7503 Intervention

## Key facts

- **NCT ID:** NCT05560607
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-12
- **Primary completion:** 2023-11-20
- **Final completion:** 2024-02-27
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05560607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05560607, "Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05560607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*